National Centre for
Pharmacoeconomics
NCPE Ireland
About Us
Current Staff
News
Glossary
Contact Us
Vacancies
Home
Submission Process
HTA Guidelines
Process Flowchart
Submission Templates
Pharmacoeconomic Evaluations
Drugs
Vaccines
Diagnostics and Other Technologies
Publications
Peer Reviewed Papers
Abstracts
Reports
Research
Pharmacoeconomic Research
Education
COVID-19
For Patients
Drugs
:
I
A
B
C
D
E
F
G
H
I
K
L
M
N
O
P
R
S
T
U
V
Z
Ibrutinib (Imbruvica®) HTA ID:20032
Ibrutinib (Imbruvica®) for CLL
Ibrutinib (Imbruvica®) for MCL
Ibrutinib (Imbruvica®) for previously untreated CLL
Ibrutinib (Imbruvica®) in combination with venetoclax. HTA ID: 22054
Icatibant (Firazyr®)
Idarucizumab (Praxbind®)
Idebenone (Raxone®)
Idelalisib (Zydelig®)
Imipenem/cilastatin/relebactam (Recarbrio®). HTA ID: 20040
1
2
3
4
5
Next Page
health check